Health and Healthcare Systems

This simple treatment could be the solution to peanut allergies

A man sorts through peanuts for sale at a shop in Peshawar, Pakistan January 5, 2017. REUTERS/Fayaz Aziz - RC1AD7B954E0

Every day for one year, 372 of the trial participants mixed the contents of an AR101 capsule into their food. Image: REUTERS/Fayaz Aziz

Kristin Houser
Writer, Futurism

A new treatment to help people with peanut allergies survive accidental exposure just moved one step closer to becoming a reality.

Aimmune Therapeutics’s AR101 takes something of a The Princess Bride approach to the problem of peanut allergies. Just like the fictional Westley used repeated exposure to desensitize himself to the poison iocane, AR101 users repeatedly expose themselves to small amounts of their “poison,” in this case, peanuts, in order to build a tolerance to it.

Issues with food labels Image: Aimmune

For their Phase 3 PALISADE efficacy trial, Aimmune treated 496 children between the ages of four and 17 with severe peanut allergies. Anything more than a tenth of a single peanut was enough to prompt an allergic reaction in these children.

Every day for one year, 372 of the trial participants mixed the contents of an AR101 capsule into their food. Each capsule contained a precise amount of peanut flour that increased over the course of the first six months of the trial, then remained steady for the remainder of the year. Aimmune gave the remaining 124 participants a placebo.

By the end of the trial, 67 percent of participants that were given AR101 could tolerate at least a 600-milligram dose of peanut protein, which is roughly equivalent to two peanuts or a small bite from a peanut butter sandwich. Only four percent of participants given the placebo tolerated the same dose.

In order for the Food and Drug Administration to approve a drug, it must statistically best a placebo by 15 percent. AR101 did far better, beating that benchmark with a difference of 53 percent. In a press release, Aimmune said they plan to submit an application for FDA approval before the end of 2018, with an application for approval in Europe to follow in the first half of 2019.

Peanuts are one of the most common food allergies, and the reaction they can cause in those who are highly allergic can be life-threatening. Children may not be as diligent as adults at avoiding peanuts, so a drug like AR101 that could decrease the severity of a reaction could give parents added peace of mind when their little ones leave the house.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Stay up to date:

Precision Medicine

Related topics:
Health and Healthcare SystemsIndustries in Depth
Share:
The Big Picture
Explore and monitor how Precision Medicine is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

The world is in the grip of a record dengue fever outbreak. What's causing it and how can it be stopped?

Shyam Bishen

November 5, 2024

Not just a number: Science is redefining how we understand ageing

About us

Engage with us

  • Sign in
  • Partner with us
  • Become a member
  • Sign up for our press releases
  • Subscribe to our newsletters
  • Contact us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2024 World Economic Forum